The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Hemophilia A and B Recombinant Factor Replacement Therapy-Global Market Insights and Sales Trends 2024
Synopsis
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
The global Hemophilia A and B Recombinant Factor Replacement Therapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hemophilia A and B Recombinant Factor Replacement Therapy in various end use industries. The expanding demands from the Hospitals, Clinics and Ambulatory Surgical Centers,, are propelling Hemophilia A and B Recombinant Factor Replacement Therapy market. Haemophilia A, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Haemophilia B segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hemophilia A and B Recombinant Factor Replacement Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hemophilia A and B Recombinant Factor Replacement Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hemophilia A and B Recombinant Factor Replacement Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hemophilia A and B Recombinant Factor Replacement Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hemophilia A and B Recombinant Factor Replacement Therapy covered in this report include Pfizer, Novo Nordisk, Baxalta, Bayer, Biogen, CSL Behring, Emergent Biosolutions, Spark therapeutics and Uniqure, etc.
The global Hemophilia A and B Recombinant Factor Replacement Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novo Nordisk
Baxalta
Bayer
Biogen
CSL Behring
Emergent Biosolutions
Spark therapeutics
Uniqure
Global Hemophilia A and B Recombinant Factor Replacement Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hemophilia A and B Recombinant Factor Replacement Therapy market, Segment by Type:
Haemophilia A
Haemophilia B
Global Hemophilia A and B Recombinant Factor Replacement Therapy market, by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hemophilia A and B Recombinant Factor Replacement Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Haemophilia is a group of inherited genetic disorders which causes abnormal or exaggerated bleeding. It impairs the normal mechanism of blood clotting after an injury. Internal bleeding inside the joint or inside brain is commonly seen in the patients with severe to moderate haemophilia. Its symptoms include bleeding from any site of the body. Internal bleeding is fatal as internal bleeding inside the joint causes joint damage and inside the brain, causes brain damage and seizers. The disease is inherited in an X-linked recessive genetic pattern, therefore males are commonly affected with haemophilia while females are usually carriers of the disease. Haemophilia A is caused by the deficiency of clotting Factor VIII, whereas haemophilia B is caused by the deficiency of Factor IX. It is also known as Christmas disease. The disease management includes factor replacement therapy. Factor replacement therapy is the infusion of factor VIII and IX concentrates through injection to control bleeding. These factor concentrates come from two sources i.e. from human plasma or from genetically engineered cell line made by recombinant DNA technology.
The global Hemophilia A and B Recombinant Factor Replacement Therapy market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Hemophilia A and B Recombinant Factor Replacement Therapy in various end use industries. The expanding demands from the Hospitals, Clinics and Ambulatory Surgical Centers,, are propelling Hemophilia A and B Recombinant Factor Replacement Therapy market. Haemophilia A, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Haemophilia B segment is estimated at % CAGR for the next seven-year period.
The global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Hemophilia A and B Recombinant Factor Replacement Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Hemophilia A and B Recombinant Factor Replacement Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Hemophilia A and B Recombinant Factor Replacement Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Hemophilia A and B Recombinant Factor Replacement Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Hemophilia A and B Recombinant Factor Replacement Therapy covered in this report include Pfizer, Novo Nordisk, Baxalta, Bayer, Biogen, CSL Behring, Emergent Biosolutions, Spark therapeutics and Uniqure, etc.
The global Hemophilia A and B Recombinant Factor Replacement Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Novo Nordisk
Baxalta
Bayer
Biogen
CSL Behring
Emergent Biosolutions
Spark therapeutics
Uniqure
Global Hemophilia A and B Recombinant Factor Replacement Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Hemophilia A and B Recombinant Factor Replacement Therapy market, Segment by Type:
Haemophilia A
Haemophilia B
Global Hemophilia A and B Recombinant Factor Replacement Therapy market, by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Hemophilia A and B Recombinant Factor Replacement Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Hemophilia A and B Recombinant Factor Replacement Therapy
1.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Overview
1.1.1 Hemophilia A and B Recombinant Factor Replacement Therapy Product Scope
1.1.2 Hemophilia A and B Recombinant Factor Replacement Therapy Market Status and Outlook
1.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Region (2018-2029)
1.4 Global Hemophilia A and B Recombinant Factor Replacement Therapy Historic Market Size by Region (2018-2023)
1.5 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2018-2029)
1.6.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2018-2029)
1.6.2 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2018-2029)
1.6.3 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2018-2029)
1.6.4 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2018-2029)
1.6.5 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size (2018-2029)
2 Hemophilia A and B Recombinant Factor Replacement Therapy Market by Type
2.1 Introduction
2.1.1 Haemophilia A
2.1.2 Haemophilia B
2.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Historic Market Size by Type (2018-2023)
2.2.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Type (2018-2029)
3 Hemophilia A and B Recombinant Factor Replacement Therapy Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Ambulatory Surgical Centers
3.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Historic Market Size by Application (2018-2023)
3.2.2 Global Hemophilia A and B Recombinant Factor Replacement Therapy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Hemophilia A and B Recombinant Factor Replacement Therapy Revenue Breakdown by Application (2018-2029)
4 Hemophilia A and B Recombinant Factor Replacement Therapy Competition Analysis by Players
4.1 Global Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Hemophilia A and B Recombinant Factor Replacement Therapy as of 2022)
4.3 Date of Key Players Enter into Hemophilia A and B Recombinant Factor Replacement Therapy Market
4.4 Global Top Players Hemophilia A and B Recombinant Factor Replacement Therapy Headquarters and Area Served
4.5 Key Players Hemophilia A and B Recombinant Factor Replacement Therapy Product Solution and Service
4.6 Competitive Status
4.6.1 Hemophilia A and B Recombinant Factor Replacement Therapy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Products, Services and Solutions
5.1.4 Pfizer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$ Million) & (2018-2023)
5.1.5 Pfizer Recent Developments
5.2 Novo Nordisk
5.2.1 Novo Nordisk Profile
5.2.2 Novo Nordisk Main Business
5.2.3 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Products, Services and Solutions
5.2.4 Novo Nordisk Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$ Million) & (2018-2023)
5.2.5 Novo Nordisk Recent Developments
5.3 Baxalta
5.3.1 Baxalta Profile
5.3.2 Baxalta Main Business
5.3.3 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Products, Services and Solutions
5.3.4 Baxalta Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$ Million) & (2018-2023)
5.3.5 Bayer Recent Developments
5.4 Bayer
5.4.1 Bayer Profile
5.4.2 Bayer Main Business
5.4.3 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Products, Services and Solutions
5.4.4 Bayer Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$ Million) & (2018-2023)
5.4.5 Bayer Recent Developments
5.5 Biogen
5.5.1 Biogen Profile
5.5.2 Biogen Main Business
5.5.3 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Products, Services and Solutions
5.5.4 Biogen Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$ Million) & (2018-2023)
5.5.5 Biogen Recent Developments
5.6 CSL Behring
5.6.1 CSL Behring Profile
5.6.2 CSL Behring Main Business
5.6.3 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Products, Services and Solutions
5.6.4 CSL Behring Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$ Million) & (2018-2023)
5.6.5 CSL Behring Recent Developments
5.7 Emergent Biosolutions
5.7.1 Emergent Biosolutions Profile
5.7.2 Emergent Biosolutions Main Business
5.7.3 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Products, Services and Solutions
5.7.4 Emergent Biosolutions Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$ Million) & (2018-2023)
5.7.5 Emergent Biosolutions Recent Developments
5.8 Spark therapeutics
5.8.1 Spark therapeutics Profile
5.8.2 Spark therapeutics Main Business
5.8.3 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Products, Services and Solutions
5.8.4 Spark therapeutics Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$ Million) & (2018-2023)
5.8.5 Spark therapeutics Recent Developments
5.9 Uniqure
5.9.1 Uniqure Profile
5.9.2 Uniqure Main Business
5.9.3 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Products, Services and Solutions
5.9.4 Uniqure Hemophilia A and B Recombinant Factor Replacement Therapy Revenue (US$ Million) & (2018-2023)
5.9.5 Uniqure Recent Developments
6 North America
6.1 North America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Hemophilia A and B Recombinant Factor Replacement Therapy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Hemophilia A and B Recombinant Factor Replacement Therapy Market Dynamics
11.1 Hemophilia A and B Recombinant Factor Replacement Therapy Industry Trends
11.2 Hemophilia A and B Recombinant Factor Replacement Therapy Market Drivers
11.3 Hemophilia A and B Recombinant Factor Replacement Therapy Market Challenges
11.4 Hemophilia A and B Recombinant Factor Replacement Therapy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
